All Topics

Technology

Art

Unapproved klotho gene therapy for longevity to be sold overseas to bypass FDA regulations

Alice Klein

2h ago· 8 min readenNews

Summary

A US-based company called Minicircle is planning to sell an unapproved gene therapy designed to boost longevity by increasing production of the anti-ageing protein klotho. The therapy will be offered at overseas clinics to bypass FDA regulations, as it has not undergone rigorous clinical trials or received approval from major regulatory bodies. This raises significant ethical and safety concerns about offering unproven medical treatments to consumers.

Source

bskyUnapproved klotho gene therapy for longevity to be sold overseas to bypass FDA regulationsnewscientist.com

Key quotes

· 3 pulled

The gene therapy, developed by Minicircle – a company headquartered in Austin, Texas – is designed to make cells produce more of an anti-ageing protein called klotho.

To get around the extensive clinical testing required by the FDA to approve a therapeutic product in the US, Minicir

This is despite the fact that it hasn't been tested in rigorous clinical trials and doesn't have approval from the US Food and Drug Administration (FDA) or other major regulators.

Snippet from the RSS feed

A gene therapy that instructs cells to produce more of an anti-ageing protein called klotho is about to be offered by a US company at overseas clinics to bypass FDA rules

You might also wanna read

Synergistic senolytic–regenerative therapy significantly extends healthspan and lifespan

link.springer.com

U.S. restrictions on Chinese biotech could harm patients, argues editorial

The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tec

economist.com·2d ago

Method to reverse cellular ageing is about to be tested in humans

nature.com·2mo ago

Inside the Grey Market Peptide Economy: Regulatory Gaps and Underground Pharmaceutical Infrastructure

This article investigates the parallel pharmaceutical infrastructure built around grey market peptides like BPC-157 and semaglutide. It cont

vectorculture.substack.com·5mo ago

Goldman Sachs Report Questions Financial Sustainability of Curative Gene Therapies

Goldman Sachs analysts question whether curing patients is a sustainable business model for biotech companies, particularly those developing